The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.

Maj-Britt JensenAnne-Vibeke LænkholmTorsten O NielsenJens Ole EriksenPernille WehnTressa HoodNamratha RamWesley BuckinghamSean FerreeBent Ejlertsen

Published in: Breast cancer research : BCR (2018)

The Prosigna ROR score and intrinsic subtypes were prognostic in high-risk premenopausal patients with breast cancer, and intrinsic subtypes identify high-risk patients with or without major benefit from adjuvant C/CMF treatment.

Keyphrases

gene expression
early stage
postmenopausal women
dna methylation
low dose
high throughput
squamous cell carcinoma
early breast cancer
combination therapy